Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Solriamfetol hydrochloride by Axsome Therapeutics for Binge Eating Disorder: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase III for Binge Eating Disorder. According to...
Solriamfetol hydrochloride by Axsome Therapeutics for Major Depressive Disorder: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase III for Major Depressive Disorder. According to...
Solriamfetol hydrochloride by Axsome Therapeutics for Shift Work Sleep Disorder: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase III for Shift Work Sleep Disorder. According...
Solriamfetol hydrochloride by Axsome Therapeutics for Fatigue: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase II for Fatigue. According to GlobalData, Phase...